Certolizumab pegol in severe rheumatoid arthritis. Real-life evidence in an Argentine cohort: goal achievement (t2t) at 3 months and predictive factors. by Rodrigo Garcia -Salinas, Sebastian Magri, Alvaro Ruta

Subjects: Get full text

Certolizumab pegol in therapy for rheumatoid arthritis by Galina Viktorovna Lukina, Ya A Sigidin

Subjects: Get full text

EFFICACY OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF PSORIATIC ARTHRITIS by T. V. Korotaeva, E. Yu. Loginova

Subjects: Get full text

CERTOLIZUMAB PEGOL IN THE TREATMENT OF TAKAYASU ARTERITIS: THE FIRST EXPERIENCE AND PROSPECTS by P. I. Novikov, I. O. Smitienko, M. V. Sokolova, S. V. Moiseev

Subjects: Get full text

A real-world pharmacovigilance study of Certolizumab pegol based on FAERS database by Meng Liu, Pan Yin, Ruihan Fan, Guanfei Zhang, Kaidi Zhao

Subjects: “…Certolizumab pegol…”
Get full text

A healthy and nuclear family of a patient with inflammatory disease: topical issues and ways of their solution. What can modern medicine offer? by A. M. Lila

Subjects: Get full text

Retention rate and predictor factors of drug discontinuation in axial spondyloarthritis: a focus on certolizumab and secukinumab by Ebru Atalar, Hatice Ecem Konak, Pınar Akyüz Dağlı, Bahar Özdemir Ulusoy, Özlem Karakaş, Kevser Orhan, Rezan Koçak Ulucaköy, Esra Kayacan Erdoğan, Serdar Can Güven, Orhan Küçükşahin, İsmail Doğan, Hakan Babaoğlu, Yüksel Maraş, Şükran Erten, Ahmet Omma, Berkan Armağan

Subjects: Get full text

Highly effective treatment options for rheumatoid arthritis afforded by the availability of biosimilars by Leticia A. Shea, Jamshaid S. Ahmed

Subjects: Get full text

Granuloma annulare treated with certolizumab following the development of antidrug antibodies to adalimumab by Ayelet I. Rubenstein, BA, Jina Chung, MD, Misha Rosenbach, MD

Subjects: Get full text

Influence of Rheumatoid Factors on the Efficacy of TNF Inhibitor Therapy in Patients with Rheumatoid Arthritis by Atsushi Nagayasu, Yusuke Miyazaki, Koshiro Sonomoto, Satoshi Kubo, Ippei Miyagawa, Ayako Yamaguchi, Hiroaki Tanaka, Yasuyuki Todoroki, Masanobu Ueno, Takafumi Aritomi, Yuya Fujita, Hidenori Sakai, Katsunori Suzuki, Shingo Nakayamada, Yoshiya Tanaka

Subjects: “…Certolizumab pegol…”
Get full text

LONG-TERM RETENTION RATE OF CERTOLIZUMAB PEGOL IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: DATA FROM THE TURKBIO REGISTRY by Ahmet Karataş, Yavuz Pehlivan, Servet Akar, Soner Şenel, Aslıhan Avanoğlu Güler, Özgül Soysal Gündüz, Ayten Yazıcı, Sema Yılmaz, Rabia Pişkin Sağır, Nevsun İnanç, Gözde Yıldırım Çetin, Mehmet Pamir Atagündüz, Fatoş Önen

Subjects: Get full text

Experience with long-term use of certolizumab pegol (Cimzia) by Karine Arnoldovna Lytkina, G P Arutyunov

Subjects: Get full text

CERTOLIZUMAB PEGOL IN THE TREATMENT OF AXIAL SPONDYLOARTHRITIS by Sh. F. Erdes

Subjects: Get full text

BIOLOGICAL THERAPY IN ADULT PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: BUDGET IMPACT ANALYSIS by E. A. Pyadushkina

Subjects: Get full text

New treatment possibilities for rheumatoid arthritis: the Russian experience in using certolizumab pegol by Dmitry Evgenyevich Karateev, E L Nasonov, L N Denisov, M L Stanislav, E Yu Panasyuk, I A Andrianova, V I Mazurov, E S Zhugrova, Yu P Uspensky, L N Belousova, E P Ilivanova, G K Matsiyevskaya, G P Aurtyunov, K A Lytkina, R S Saikovsky, V N Ardashev, E V Zhilyaev, N I Korshunov

Subjects: Get full text

Experience with early use of certolizumab pegol in able-bodied patients with axial spondyloarthritis in the framework of a model for clinical statistical groups by Yu. Yu. Grabovetskaya

Subjects: Get full text

Cost-effectiveness study of treatment with biologic disease-modifying antirheumatic drugs in adult patients with active ankylosing spondylitis by R. O. Dreval

Subjects: Get full text